773873-72-6 Usage
General Description
Methyl 3,4,5-trifluorobenzenecarboxylate is a chemical compound with the molecular formula C9H5F3O2. It is a fluoroaromatic ester and is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. METHYL 3,4,5-TRIFLUOROBENZENECARBOXYLATE is a colorless liquid with a strong odor, and it is highly flammable. Methyl 3,4,5-trifluorobenzenecarboxylate is stable under normal temperatures and pressures, but may decompose when exposed to high temperatures. It is important to handle and store this chemical compound with care, as it can be harmful if ingested, inhaled, or absorbed through the skin. Additionally, it may cause irritation to the skin, eyes, and respiratory system upon contact.
Check Digit Verification of cas no
The CAS Registry Mumber 773873-72-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,7,3,8,7 and 3 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 773873-72:
(8*7)+(7*7)+(6*3)+(5*8)+(4*7)+(3*3)+(2*7)+(1*2)=216
216 % 10 = 6
So 773873-72-6 is a valid CAS Registry Number.
InChI:InChI=1/C8H5F3O2/c1-13-8(12)4-2-5(9)7(11)6(10)3-4/h2-3H,1H3
773873-72-6Relevant articles and documents
MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE
-
Paragraph 00463, (2018/08/20)
The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.